Immunotherapy Advances in Small Cell Lung Cancer

Small cell lung cancer (SCLC) is aggressive and often difficult to treat, but many patients may have new hope. On August 17, 2018, the FDA approved the first immunotherapy the checkpoint inhibitor nivolumab (Opdivo, Bristol-Myers Squibb for patients with small cell lung cancer. Since this approval, there has been renewed focus on how to make different immunotherapies work for a disease which typicallly comprises 10-15% of all lung cancer cases. In this webinar for patients and caregivers, Matthew Hellmann, M.D., of Memorial Sloan Kettering Cancer Center discusses the new FDA approval, clinical trials, and potential treatments for patients with small cell lung cancer.